



PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Vectibix

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Form with fields for Patient Name, Member/Subscriber Number, Date of Birth, Group Number, Address, City, State ZIP, Primary Phone, Prescriber Name, Supervising Physician, Fax, Office Contact, NPI, Address, City, State ZIP, Specialty/facility name, and State Lic ID.

Drug Name and Strength:

Directions / SIG:

Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.

Q1. What diagnosis is this drug being prescribed for?
Q2. If you selected "other" in question 1, please provide documentation that use is consistent with a category 1 recommendation per NCCN compendia or guidelines.
Q3. Please provide ICD code(s) for diagnosis
Q4. Is the prescribing physician from the division of hematology/oncology?
Q5. Is the patient a new start to therapy?
Q6. Does the patient have a documented RAS gene mutation testing that shows tumor expressing RAS wild type (both KRAS and NRAS)?



# PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

## Vectibix

Phone: 800-728-7947

Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

<b>Patient Name:</b>	<b>Prescriber Name:</b> <b>Supervising Physician:</b>
Q7. Will Vectibix be used for first-line treatment in combination with FOLFOX? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q8. Will Vectibix be used as monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Q9. Who is the ENTITY that will be submitting the CLAIM for the DRUG and seeking reimbursement? <input type="checkbox"/> Pharmacy <input type="checkbox"/> Individual prescriber <input type="checkbox"/> Provider or specialty group <input type="checkbox"/> Facility <input type="checkbox"/> Other (please specify)	
Q10. Provide name and NPI of the billing entity	
Q11. Will the claim for the drug be submitted as a MEDICAL claim or PHARMACY claim (Note: If a pharmacy will be submitting a MEDICAL claim for drug reimbursement, answer MEDICAL)? <input type="checkbox"/> Medical <input type="checkbox"/> Pharmacy	
Q12. Additional Comments	

\_\_\_\_\_  
Prescriber Signature

\_\_\_\_\_  
Date

Expedited/Urgent - By checking this box and signing above, I certify that applying the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function



# PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

## Vectibix

Phone: 800-728-7947

Fax back to: 866-880-4532

---

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

---

<b>Patient Name:</b>	<b>Prescriber Name:</b> <b>Supervising Physician:</b>
----------------------	--

---

Lack of the necessary documentation may result in a medical necessity denial. Requesting providers may speak to a SWHP pharmacist or medical director at 1-800-728-7947 regarding the case to have an opportunity to help impact the decision on a request before coverage has been decided.

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document